Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort.
Georgina V. Long(The University of Sydney), Matteo S. Carlino(The University of Sydney), Alexander Guminski(The University of Sydney), Alexander M. Menzies(The University of Sydney), Bernie Fitzharris(Christchurch Hospital), John A. Thompson(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Jonathan Cebon(La Trobe University), Nageatte Ibrahim(Merck & Co., Inc., Rahway, NJ, USA (United States)), Xinxin Shu(Georgetown University), Michael B. Atkins(Georgetown University), Catriona M. McNeil(Chris O’Brien Lifehouse), Andrew Hill(University of Auckland), Richard Kefford(Broad Institute), Antoni Ribas(University of California, Los Angeles), F. Stephen Hodi(Harvard University), Wen‐Jen Hwu(The University of Texas MD Anderson Cancer Center), Michael B. Jameson(Waikato Hospital), Victoria Atkinson(Greenslopes Private Hospital), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 48
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k